$ABVC
ABVC BIOPHARMA, INC. Stock $abvc

$abvc Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023067113 Filed on August 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$15.88K	$6.109K	$312.9K
YoY Change	-62.42%	-98.05%	895.07%
Cost Of Revenue	$29.61K	$72.98K	$8.367K
YoY Change	175.71%	772.25%	1195.2%
Gross Profit	-$13.73K	-$66.87K	$304.5K
YoY Change	-143.55%	-121.96%	888.77%
Gross Profit Margin	-86.44%	-1094.65%	97.33%
Selling, General & Admin	$1.182M	$1.387M	$1.593M
YoY Change	-63.25%	-12.94%	29.32%
% of Gross Profit			523.11%
Research & Development	$141.3K	$514.4K	$532.8K
YoY Change	-53.74%	-3.44%	48.46%
% of Gross Profit			174.97%
Depreciation & Amortization	$7.459K	$6.997K	$5.490K
YoY Change	15.43%	27.45%	86.73%
% of Gross Profit			1.8%
Operating Expenses	$2.141M	$2.127M	$2.351M
YoY Change	-42.86%	-9.54%	13.79%
Operating Profit	-$2.155M	-$2.194M	-$2.047M
YoY Change	-42.01%	7.18%	0.56%
Interest Expense	$1.219M	$114.8K	$14.76K
YoY Change	863.07%	677.56%	-82.15%
% of Operating Profit
Other Income/Expense, Net	-$1.214M	-$39.69K	$17.08K
YoY Change	2050.52%	-332.42%	-122.18%
Pretax Income	-$3.369M	-$2.234M	-$2.030M
YoY Change	-10.69%	10.04%	-3.92%
Income Tax	-$999.00	$81.70K	-$82.45K
% Of Pretax Income
Net Earnings	-$3.318M	-$2.264M	-$1.859M
YoY Change	-10.46%	21.76%	-5.71%
Net Earnings / Revenue	-20885.9%	-37052.07%	-594.19%
Basic Earnings Per Share	-$0.82	-$0.68	-$0.06
Diluted Earnings Per Share	-$0.82	-$0.68	-$0.06
COMMON SHARES
Basic Shares Outstanding	3.951M shares	33.08M shares	31.31M shares
Diluted Shares Outstanding	4.055M shares	3.309M shares	31.31M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$568.6K	$176.1K	$2.993M
YoY Change	-59.42%	-94.12%	223.66%
Cash & Equivalents	$500.1K	$99.29K	$2.911M
Short-Term Investments	$68.52K	$76.79K	$82.76K
Other Short-Term Assets	$764.0K	$790.9K	$2.629M
YoY Change	-18.18%	-69.92%	69.62%
Inventory			$21.86K
Prepaid Expenses
Receivables	$1.530K	$12.36K	$289.5K
Other Receivables	$535.0K	$526.2K	$3.713M
Total Short-Term Assets	$2.494M	$2.129M	$9.789M
YoY Change	-14.11%	-78.25%	169.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.954M	$564.3K	$597.3K
YoY Change	1303.43%	-5.52%	-72.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$2.677M	$831.7K	$870.6K
YoY Change	228.05%	-4.46%	-20.55%
Other Assets	$1.636M	$3.510M	$1.231M
YoY Change	-66.95%	185.19%	-40.64%
Total Long-Term Assets	$14.10M	$7.192M	$3.993M
YoY Change	86.05%	80.1%	-24.9%
TOTAL ASSETS
Total Short-Term Assets	$2.494M	$2.129M	$9.789M
Total Long-Term Assets	$14.10M	$7.192M	$3.993M
Total Assets	$16.59M	$9.320M	$13.78M
YoY Change	58.31%	-32.38%	54.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable			$2.085K
YoY Change			-58.71%
Accrued Expenses	$3.558M	$3.441M	$1.247M
YoY Change	196.15%	175.99%	-43.39%
Deferred Revenue	$79.50K
YoY Change
Short-Term Debt	$852.5K	$882.8K	$1.574M
YoY Change	-54.32%	-43.92%	-14.54%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.363M	$5.773M	$3.646M
YoY Change	37.72%	58.34%	-16.69%
LONG-TERM LIABILITIES
Long-Term Debt	$1.654M	$3.300M	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$512.8K	$614.8K	$956.3K
YoY Change	-42.58%	-35.71%	-27.36%
Total Long-Term Liabilities	$2.167M	$3.915M	$956.3K
YoY Change	142.63%	309.37%	-76.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.363M	$5.773M	$3.646M
Total Long-Term Liabilities	$2.167M	$3.915M	$956.3K
Total Liabilities	$7.530M	$9.687M	$4.602M
YoY Change	57.29%	110.5%	-38.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$62.31M	-$58.99M	-$46.34M
YoY Change	24.52%	27.31%
Common Stock	$4.823K	$3.308K	$32.31K
YoY Change	-85.22%	-89.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$9.100M	$9.100M	$9.100M
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	$9.100M	-$379.3K	$9.334M
YoY Change
Total Liabilities & Shareholders Equity	$16.59M	$9.320M	$13.78M
YoY Change	58.31%	-32.38%	54.08%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$3.318M	-$2.264M	-$1.859M
YoY Change	-10.46%	21.76%	-5.71%
Depreciation, Depletion And Amortization	$7.459K	$6.997K	$5.490K
YoY Change	15.43%	27.45%	86.73%
Cash From Operating Activities	-$1.356M	-$899.8K	-$3.429M
YoY Change	164.04%	-73.76%	137.49%
INVESTING ACTIVITIES
Capital Expenditures	$21.20K	$0.00	-$22.03K
YoY Change	-587.36%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$53.16K	-$440.6K	$0.00
YoY Change	-96.5%		-100.0%
Cash From Investing Activities	-$74.36K	-$440.6K	-$22.03K
YoY Change	-95.12%	1899.91%	-84.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.652M	-31.59K	3.664M
YoY Change	173.66%	-100.86%	-3232.64%
NET CHANGE
Cash From Operating Activities	-1.356M	-899.8K	-3.429M
Cash From Investing Activities	-74.36K	-440.6K	-22.03K
Cash From Financing Activities	1.652M	-31.59K	3.664M
Net Change In Cash	220.8K	-1.372M	212.5K
YoY Change	-115.4%	-745.53%	-112.5%
FREE CASH FLOW
Cash From Operating Activities	-$1.356M	-$899.8K	-$3.429M
Capital Expenditures	$21.20K	$0.00	-$22.03K
Free Cash Flow	-$1.378M	-$899.8K	-$3.407M
YoY Change	170.46%	-73.59%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40700
	dei	Entity Registrant Name EntityRegistrantName	ABVC BioPharma, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-0014658
	dei	Entity Address Address Line1 EntityAddressAddressLine1	44370 Old Warm Springs Blvd.
	dei	Entity Address City Or Town EntityAddressCityOrTown	Fremont
	dei	Entity Address Country EntityAddressCountry	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94538
	dei	City Area Code CityAreaCode	(510)
	dei	Local Phone Number LocalPhoneNumber	668-0881
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	ABVC
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3951388	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99290	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85265	usd
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	642899	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1306463	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12358	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	98325	usd
CY2023Q2	abvc	Accounts Receivable Related Parties Net Accounts Receivable Related Parties Net AccountsReceivableRelatedPartiesNetAccountsReceivableRelatedPartiesNet	623245	usd
CY2022Q4	abvc	Accounts Receivable Related Parties Net Accounts Receivable Related Parties Net AccountsReceivableRelatedPartiesNetAccountsReceivableRelatedPartiesNet	757343	usd
CY2023Q2	abvc	Due From Related Party Current DueFromRelatedPartyCurrent	526216	usd
CY2022Q4	abvc	Due From Related Party Current DueFromRelatedPartyCurrent	513819	usd
CY2023Q2	us-gaap	Short Term Investments ShortTermInvestments	76787	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	75797	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	148024	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	150235	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	2128819	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2987247	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	564344	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	573978	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	999645	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1161141	usd
CY2023Q2	us-gaap	Long Term Investments LongTermInvestments	831706	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	842070	usd
CY2023Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	35472	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	117110	usd
CY2023Q2	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	133472	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	135135	usd
CY2023Q2	us-gaap	Security Deposit SecurityDeposit	61992	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	58838	usd
CY2023Q2	abvc	Prepayment For Longterm Investments Noncurrent PrepaymentForLongtermInvestmentsNoncurrent	3279153	usd
CY2022Q4	abvc	Prepayment For Longterm Investments Noncurrent PrepaymentForLongtermInvestmentsNoncurrent	2838578	usd
CY2023Q2	abvc	Due From Related Parties Noncurrent Amount DueFromRelatedPartiesNoncurrentAmount	1285804	usd
CY2022Q4	abvc	Due From Related Parties Noncurrent Amount DueFromRelatedPartiesNoncurrentAmount	1141378	usd
CY2023Q2	us-gaap	Assets Assets	9320407	usd
CY2022Q4	us-gaap	Assets Assets	9855475	usd
CY2023Q2	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	882750	usd
CY2022Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	1893750	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3441365	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2909587	usd
CY2023Q2	us-gaap	Customer Advances Current CustomerAdvancesCurrent	79501	usd
CY2022Q4	us-gaap	Customer Advances Current CustomerAdvancesCurrent	10985	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	390505	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	369314	usd
CY2023Q2	abvc	Due To Related Parties DueToRelatedParties	978734	usd
CY2022Q4	abvc	Due To Related Parties DueToRelatedParties	635893	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5772855	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5819529	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2659540	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2783909	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	514442	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	532782	usd
CY2023Q2	us-gaap	Security Deposit Liability SecurityDepositLiability	5680	usd
CY2022Q4	us-gaap	Security Deposit Liability SecurityDepositLiability	7980	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	609140	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	791827	usd
CY2023Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	3299742	usd
CY2023Q2	us-gaap	Liabilities Liabilities	9687417	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6619336	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	68077777	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	67937050	usd
CY2023Q2	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	902960	usd
CY2022Q4	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	1354440	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58991645	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-54904439	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-534205	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-517128	usd
CY2023Q2	us-gaap	Treasury Stock Value TreasuryStockValue	9100000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	9100000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-379315	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3098585	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	12305	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	137554	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-367010	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3236139	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9320407	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9855475	usd
CY2023Q2	us-gaap	Revenues Revenues	6109	usd
CY2022Q2	us-gaap	Revenues Revenues	312860	usd
	us-gaap	Revenues Revenues	134381	usd
	us-gaap	Revenues Revenues	338520	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	72981	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	8367	usd
	us-gaap	Cost Of Revenue CostOfRevenue	133217	usd
	us-gaap	Cost Of Revenue CostOfRevenue	10263	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	-66872	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	304493	usd
	us-gaap	Gross Profit GrossProfit	1164	usd
	us-gaap	Gross Profit GrossProfit	328257	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1386788	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1592831	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	849421	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	892186	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	225740	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	225740	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	592229	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4917743	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	2126970	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	2351353	usd
	us-gaap	Operating Expenses OperatingExpenses	4101190	usd
	us-gaap	Operating Expenses OperatingExpenses	8593838	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2193842	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2046860	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4100026	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8265581	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	55041	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	39015	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	107752	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	79190	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	114752	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	14758	usd
	us-gaap	Interest Expense InterestExpense	171415	usd
	us-gaap	Interest Expense InterestExpense	32971	usd
CY2023Q2	abvc	Rent Income RentIncome	34800	usd
CY2022Q2	abvc	Rent Income RentIncome	32802	usd
	abvc	Rent Income RentIncome	56900	usd
	abvc	Rent Income RentIncome	56926	usd
CY2023Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-18305	usd
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	10479	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-30566	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	18042	usd
CY2023Q2	us-gaap	Other Income OtherIncome	3528	usd
CY2022Q2	us-gaap	Other Income OtherIncome	-50462	usd
	us-gaap	Other Income OtherIncome	6595	usd
	us-gaap	Other Income OtherIncome	-59872	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-39688	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	17076	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-30734	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	61315	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2233530	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2029784	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4130760	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8204266	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	81695	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-82451	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	81695	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-169318	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-2315225	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-1947333	usd
	us-gaap	Profit Loss ProfitLoss	-4212455	usd
	us-gaap	Profit Loss ProfitLoss	-8034948	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-51714	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-88336	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-125249	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-180511	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2263511	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1858997	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4087206	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7854437	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-12032	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-123221	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	17077	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-236560	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2275543	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1982218	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4070129	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8090997	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.68
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.59
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.24
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.65
	us-gaap	Profit Loss ProfitLoss	-4212455	usd
	us-gaap	Profit Loss ProfitLoss	-8034948	usd
	us-gaap	Depreciation Depreciation	13490	usd
	us-gaap	Depreciation Depreciation	10902	usd
	abvc	Stock Based Compensation For Non Employees StockBasedCompensationForNonEmployees	592229	usd
	abvc	Stock Based Compensation For Non Employees StockBasedCompensationForNonEmployees	4917743	usd
	us-gaap	Provision For Other Losses ProvisionForOtherLosses	38500	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-122784	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-18831	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	81695	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-170118	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-181565	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8782	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-720	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	784714	usd
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-2300	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	156823	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	2435935	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2473	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2085	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	531778	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-21915	usd
	us-gaap	Increase Decrease In Customer Advances IncreaseDecreaseInCustomerAdvances	68516	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	342841	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	80760	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2397460	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6423618	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	115246	usd
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	440575	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-440575	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-115246	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3663925	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	3175000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2175000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3663925	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13496	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-91030	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-649539	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2965969	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1391728	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6565215	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	742189	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3599246	usd
	us-gaap	Interest Paid Net InterestPaidNet	21532	usd
	us-gaap	Interest Paid Net InterestPaidNet	24348	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8870342	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	8130188	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	451480	usd
	us-gaap	Profit Loss ProfitLoss	-8034948	usd
	abvc	Cumulative Transaction Adjustments CumulativeTransactionAdjustments	-236560	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9180502	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3236139	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	140749	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	451480	usd
	us-gaap	Profit Loss ProfitLoss	-4212455	usd
	abvc	Cumulative Transaction Adjustments CumulativeTransactionAdjustments	17077	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-367010	usd
CY2023Q2	abvc	Net Loss NetLoss	2315225	usd
	abvc	Net Loss NetLoss	4212455	usd
CY2023Q2	us-gaap	Capital Capital	3644036	usd
CY2023Q2	us-gaap	Derivative Collateral Right To Reclaim Cash DerivativeCollateralRightToReclaimCash	2397460	usd
CY2023Q2	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	610542	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Reclassifications of Prior Year Presentation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior year unaudited consolidated balance sheet and unaudited consolidated cash flow statement amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2016Q1	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	forward split at a ratio of 1 to 3.141
CY2016Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Excess Stock Shares Authorized ExcessStockSharesAuthorized	360000000	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99290	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85265	usd
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	642899	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1306463	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentration of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation’s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company performs ongoing credit evaluation of our customers and requires no collateral. An allowance for doubtful accounts is provided based on a review of the collectability of accounts receivable. The Company determines the amount of allowance for doubtful accounts by examining its historical collection experience and current trends in the credit quality of its customers as well as its internal credit policies. Actual credit losses may differ from our estimates.</p>
	us-gaap	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivable	0.9728	pure
CY2022	us-gaap	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivable	0.7189	pure
CY2022Q4	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	618150	usd
CY2022Q3	abvc	Principal Amount principalAmount	7500000	twd
	abvc	Impairment Of Equity Investments ImpairmentOfEquityInvestments	0	usd
	abvc	Impairment Of Equity Investments ImpairmentOfEquityInvestments	0	usd
	abvc	Schedule Of Ownership Percentages Of Investee Table Text Blocks ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks	<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ownership percentages of each investee are listed as follows:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ownership percentage</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Accounting</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name of related party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">treatments</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Braingenesis Biotechnology Co., Ltd.</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">0.22</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">0.22</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Genepharm Biotech Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.92</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.92</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">BioHopeKing Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.03</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.03</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">BioFirst Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21.77</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21.77</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Equity Method</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rgene Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28.85</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28.85</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Equity Method</td></tr> </table>
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	1893750	usd
	abvc	Labour Pension Fund Percentage LabourPensionFundPercentage	0.06	pure
	abvc	Percentage Of Monthly Contributions PercentageOfMonthlyContributions	0.06	pure
CY2023Q2	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	2455	usd
CY2022Q2	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	3309	usd
	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	5259	usd
	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	6646	usd
	abvc	Stock Based Compensation For Employees StockBasedCompensationForEmployees	0	usd
	abvc	Stock Based Compensation For Employees StockBasedCompensationForEmployees	0	usd
CY2023Q2	abvc	Stock Based Compensation For Employees StockBasedCompensationForEmployees	0	usd
CY2022Q2	abvc	Stock Based Compensation For Employees StockBasedCompensationForEmployees	0	usd
CY2023Q2	abvc	Stock Based Compensation For Nonemployees StockBasedCompensationForNonemployees	225740	usd
CY2022Q1	abvc	Stock Based Compensation For Nonemployees StockBasedCompensationForNonemployees	225740	usd
	abvc	Stock Based Compensation For Non Employees StockBasedCompensationForNonEmployees	592229	usd
	abvc	Stock Based Compensation For Non Employees StockBasedCompensationForNonEmployees	4917743	usd
	abvc	Beneficial Conversion Feature BeneficialConversionFeature	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Beneficial Conversion Feature</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company may issue convertible notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.</p>
	abvc	Defined Benefit Plan Funded Percentages DefinedBenefitPlanFundedPercentages	0.50	pure
CY2023Q2	abvc	Nonmarketable Cost Method Investments Net NonmarketableCostMethodInvestmentsNet	831706	usd
CY2022Q4	abvc	Nonmarketable Cost Method Investments Net NonmarketableCostMethodInvestmentsNet	842070	usd
	abvc	Milestone Payments Royalty Percentage MilestonePaymentsRoyaltyPercentage	0.12	pure
CY2018Q4	abvc	Co Dev Agreement Description CoDevAgreementDescription	the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene’s Common Stock, at the price of NT$50 (approximately equivalent to $1.64 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549.
CY2022Q2	abvc	Amount Received AmountReceived	3000000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3878334	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3878435	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3313990	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3304457	usd
CY2023Q2	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	564344	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	573978	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6997	usd
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5491	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13490	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10902	usd
CY2023Q2	us-gaap	Equity Method Investments EquityMethodInvestments	831706	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	842070	usd
	abvc	Purchase Additional Shares PurchaseAdditionalShares	317000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.2885	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.2885	pure
CY2023Q1	us-gaap	Payments For Previous Acquisition PaymentsForPreviousAcquisition	3175000	usd
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.05
CY2023Q1	us-gaap	Shares Issued SharesIssued	5291667	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.05
CY2023Q2	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	308650.58	usd
	abvc	Percentage Of Average Amount PercentageOfAverageAmount	0.90	pure
	abvc	Percentage Of Cash Permium PercentageOfCashPermium	0.05	pure
CY2023Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	882750	usd
CY2022Q3	abvc	Principal Amount principalAmount	240750	usd
CY2022Q3	us-gaap	Debt Instrument Term DebtInstrumentTerm	P1Y
CY2019Q1	us-gaap	Debt Instrument Repurchased Face Amount DebtInstrumentRepurchasedFaceAmount	1000000	usd
CY2019Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.05	pure
CY2020Q2	abvc	Received Loan Amount ReceivedLoanAmount	350000	usd
CY2020Q4	abvc	Received Loan Amount ReceivedLoanAmount	350000	usd
CY2021Q4	abvc	Principal Amount principalAmount	650000	usd
CY2022	abvc	Outstanding Balance OutstandingBalance	1000000	usd
CY2023Q2	abvc	Accounts Receivable Due From Related Parties AccountsReceivableDueFromRelatedParties	623245	usd
CY2022Q4	abvc	Accounts Receivable Due From Related Parties AccountsReceivableDueFromRelatedParties	757343	usd
CY2023Q2	abvc	Due From Related Parties Current Amount DueFromRelatedPartiesCurrentAmount	526216	usd
CY2022Q4	abvc	Due From Related Parties Current Amount DueFromRelatedPartiesCurrentAmount	513819	usd
CY2023Q2	abvc	Due From Other Related Parties Noncurrent Amount DueFromOtherRelatedPartiesNoncurrentAmount	1285804	usd
CY2022Q4	abvc	Due From Other Related Parties Noncurrent Amount DueFromOtherRelatedPartiesNoncurrentAmount	1141378	usd
CY2022Q2	abvc	Aggregate Principal Amount AggregatePrincipalAmount	1000000	usd
CY2022Q2	abvc	Bears Interest BearsInterest	0.05	pure
CY2022Q2	abvc	Working Capital Percentage WorkingCapitalPercentage	0.064	pure
CY2022Q2	abvc	Gross Proceeds GrossProceeds	4220000	usd
CY2022Q2	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	556075	usd
CY2022Q2	abvc	Warrants Term WarrantsTerm	P5Y
CY2022Q2	abvc	Description Of Conversion Price DescriptionOfConversionPrice	The Company may convert the Note at any time into shares of Rgene’s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided.
	us-gaap	Shortterm Debt Average Outstanding Amount ShorttermDebtAverageOutstandingAmount	500000	usd
CY2022	us-gaap	Shortterm Debt Average Outstanding Amount ShorttermDebtAverageOutstandingAmount	500000	usd
	us-gaap	Accounts Receivable Noncurrent Accrued Interest Writeoff AccountsReceivableNoncurrentAccruedInterestWriteoff	26126	usd
CY2022	us-gaap	Accounts Receivable Noncurrent Accrued Interest Writeoff AccountsReceivableNoncurrentAccruedInterestWriteoff	13819	usd
CY2022	abvc	Loan Agreement Total Amount LoanAgreementTotalAmount	507000	usd
CY2023Q2	abvc	Interest Rate InterestRate	0.065	pure
CY2023Q2	abvc	Due Amount DueAmount	111434	usd
CY2022Q4	abvc	Due Amount DueAmount	112822	usd
	abvc	Schedule Of Related Party Transactions Amount Due To Related Party ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty	Amount due to related parties consisted of the following as of the periods indicated:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">BioFirst Corporation</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">495,753</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">188,753</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">BioFirst (Australia)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">313,606</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">275,901</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">The Jiangs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,789</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,789</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Due to shareholders</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">149,586</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">151,450</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 0.125in">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">978,734</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">635,893</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>
CY2023Q2	abvc	Due To Related Party Current And Noncurrent DueToRelatedPartyCurrentAndNoncurrent	978734	usd
CY2022Q4	abvc	Due To Related Party Current And Noncurrent DueToRelatedPartyCurrentAndNoncurrent	635893	usd
CY2023Q2	abvc	Outstanding Advance From Related Party OutstandingAdvanceFromRelatedParty	495753	usd
CY2022Q4	abvc	Outstanding Advance From Related Party OutstandingAdvanceFromRelatedParty	188753	usd
CY2018	us-gaap	Debt Instrument Interest Rate Terms DebtInstrumentInterestRateTerms	The advances bear interest rate of 12% per annum.
CY2023Q2	abvc	Outstanding Principal And Accrued Interest OutstandingPrincipalAndAccruedInterest	149586	usd
CY2022Q4	abvc	Outstanding Principal And Accrued Interest OutstandingPrincipalAndAccruedInterest	151450	usd
CY2023Q2	us-gaap	Interest And Debt Expense InterestAndDebtExpense	5171	usd
CY2022Q2	us-gaap	Interest And Debt Expense InterestAndDebtExpense	5401	usd
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	10067	usd
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	10714	usd
CY2022Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	2000000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.45
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	223411	shares
CY2023Q1	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	3704167	usd
CY2023Q1	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	3175000	usd
	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	81695	usd
	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-169318	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	81695	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-169318	usd
	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	81695	usd
	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	-169318	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	701992	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	709961	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	5679314	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	5866623	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	213482	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	213482	usd
CY2023Q2	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	213482	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	213482	usd
CY2023Q2	us-gaap	Other Deferred Costs Gross OtherDeferredCostsGross	6381306	usd
CY2022Q4	us-gaap	Other Deferred Costs Gross OtherDeferredCostsGross	6576584	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6345834	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6459474	usd
CY2023Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	35472	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	117110	usd
CY2022Q1	abvc	Consulting Fees ConsultingFees	4296763	usd
CY2022Q1	abvc	Unrestricted Common Shares UnrestrictedCommonShares	1306007	shares
CY2022Q2	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	2000000	shares
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.05
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5291667	shares
CY2023Q1	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	1.05
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	The above-mentioned equity is before the reverse stock split in 2023.
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	545182	shares
CY2020Q4	abvc	Conversion Price ConversionPrice	2
CY2020Q4	abvc	Consulting Fees ConsultingFees	1090361	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	545182	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1280002	shares
CY2021Q4	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	3
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	761920	shares
CY2022Q2	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	3
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0279	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8386	pure
CY2022	abvc	Fair Value Of Options Granted FairValueOfOptionsGranted	2.79	usd
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions	0	usd
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions	0	usd
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	97577	usd
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	88270	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	191876	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2263511	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1858997	usd
CY2023Q2	abvc	Weightedaverage Shares Outstanding Basic WeightedaverageSharesOutstandingBasic	3308074
CY2022Q2	abvc	Weightedaverage Shares Outstanding Basic WeightedaverageSharesOutstandingBasic	3130733
CY2023Q2	abvc	Weighted Average Number Of Shares Diluted WeightedAverageNumberOfSharesDiluted	3308074
CY2022Q2	abvc	Weighted Average Number Of Shares Diluted WeightedAverageNumberOfSharesDiluted	3130733
CY2023Q2	abvc	Loss Per Share Basic LossPerShareBasic	-0.68
CY2022Q2	abvc	Loss Per Share Basic LossPerShareBasic	-0.59
CY2023Q2	abvc	Loss Per Share Diluted LossPerShareDiluted	-0.68
CY2022Q2	abvc	Loss Per Share Diluted LossPerShareDiluted	-0.59
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4087206	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7854437	usd
	abvc	Weightedaverage Shares Outstanding Basic WeightedaverageSharesOutstandingBasic	3307826
	abvc	Weightedaverage Shares Outstanding Basic WeightedaverageSharesOutstandingBasic	2968340
	abvc	Weighted Average Number Of Shares Diluted WeightedAverageNumberOfSharesDiluted	3307826
	abvc	Weighted Average Number Of Shares Diluted WeightedAverageNumberOfSharesDiluted	2968340
	abvc	Loss Per Share Basic LossPerShareBasic	-1.24
	abvc	Loss Per Share Basic LossPerShareBasic	-2.65
	abvc	Loss Per Share Diluted LossPerShareDiluted	-1.24
	abvc	Loss Per Share Diluted LossPerShareDiluted	-2.65
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	999645	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1161141	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	390505	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	369314	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	609140	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	791827	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	174127	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	191876	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	174127	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y5M1D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y5M23D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0152	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0149	pure
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	194567	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	403223	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	351120	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	56915	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1005825	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6180	usd
CY2023Q2	abvc	Present Value Of Future Minimum Lease Payment Sale Leaseback Transactions PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions	999645	usd
	us-gaap	Provision For Other Losses ProvisionForOtherLosses		usd
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits		usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable		usd
	us-gaap	Increase Decrease In Customer Advances IncreaseDecreaseInCustomerAdvances		usd
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2023Q2	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost		usd
CY2022Q2	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost		usd
	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost		usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001173313

Files In Submission

Name	View Source	Status
0001213900-23-067113-index-headers.html	Edgar Link	pending
0001213900-23-067113-index.html	Edgar Link	pending
0001213900-23-067113.txt	Edgar Link	pending
0001213900-23-067113-xbrl.zip	Edgar Link	pending
abvc-20230630.xsd	Edgar Link	pending
f10q0623ex31-1_abvcbio.htm	Edgar Link	pending
f10q0623ex31-2_abvcbio.htm	Edgar Link	pending
f10q0623ex32-1_abvcbio.htm	Edgar Link	pending
f10q0623ex32-2_abvcbio.htm	Edgar Link	pending
f10q0623_abvcbio.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
abvc-20230630_cal.xml	Edgar Link	unprocessable
abvc-20230630_def.xml	Edgar Link	unprocessable
abvc-20230630_lab.xml	Edgar Link	unprocessable
abvc-20230630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10q0623_abvcbio_htm.xml	Edgar Link	completed
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABVC
ABVC BIOPHARMA, INC. Stock $abvc

2023 Q3 Form 10-Q Financial Statement

#000121390023067113 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABVC ABVC BIOPHARMA, INC. Stock $abvc

2023 Q3 Form 10-Q Financial Statement

#000121390023067113 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABVC
ABVC BIOPHARMA, INC. Stock $abvc